We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

AlgoNomics Granted Patent Rights for Epibase

AlgoNomics Granted Patent Rights for Epibase

AlgoNomics Granted Patent Rights for Epibase

AlgoNomics Granted Patent Rights for Epibase

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "AlgoNomics Granted Patent Rights for Epibase"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

AlgoNomics NV has announced that notice of grant has been received from the European Patent Office for a key patent covering its Epibase® technology.

Epibase® is applied for the immunogenicity screening and optimization of biotherapeutics, such as therapeutic antibodies, biosimilars and vaccines.

The patent relates to AlgoNomics’ method to identify T-cell epitopes through the physicochemical interactions of the epitopes with their HLA Class-I and Class-II receptors.

Philippe Stas, COO of AlgoNomics: “We provide the state of the art in modeling of proteins, and this patent confirms our pioneering role in the field of immunogenicity screening and epitope identification.”

According to Dr. Lasters, CEO of AlgoNomics, “This patent confirms our innovative position as a world-leader in immunogenicity assessment of protein therapeutics”.

The patent titled “Method for predicting the binding affinity of MHC/peptide complexes” was filed in 2003, and can be found under European patent no. 1516275.